| Budget Amount *help |
¥18,590,000 (Direct Cost: ¥14,300,000、Indirect Cost: ¥4,290,000)
Fiscal Year 2014: ¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2013: ¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2012: ¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2011: ¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2010: ¥3,120,000 (Direct Cost: ¥2,400,000、Indirect Cost: ¥720,000)
|
|---|
| Outline of Final Research Achievements |
It is quite important to accumulate scientific data, promote science-based industrial development and harmonize regulatory issues for cell-based therapy in pediatric cardiology. However, heart transplantation, artificial device, and cell-based therapy have been applied to adult patients with severe heart failure, but not to pediatric patients. In this study, we aim to establish a therapeutic strategy to children with heart failure, and provide the important areas of cell-based therapy with somatic cells such as skeletal myocytes and cardiomyocytes under both the Medical affairs law and Pharmaceutical affairs law. This study addresses critical issues in the field, exchanges new ideas and disseminates the latest developments in basic research and clinical translation focusing on cell-based therapy to patients with heart failure.
|
